Funding Rounds
EG 427

EG 427 Series A (2023, $5M)

EG 427

Developing pinpoint gene therapy.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series A

Raised Amount: $5.57M